Abstract:Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC FAS/CD95 has been known as a typical death receptor that enhances cell apoptosis mainly in the immune system. Recent studies indicate that CD95 expression is rarely absent or down-regulated in solid tumors and CD95L, the cognate ligand that binds cell membrane CD95, is constantly shown to be elevated in patient serum as well as tumor microenviroment, raising the question whether CD95 acturally enhances tumorigenesis and through what mechanisms. By stably knocking down endogeneous CD95 expression level using lentivirus based shRNA in six different tumor cell lines that represent liver (HepG2), colon (HCT116), renal (CAKI-1), breast (MCF7), ovary (SKOV3ip1 and HeyA8), in all cases the CD95 knockdown tumor cell lines show a clear reduction in proliferation rate comparing with the corresponding vector control cells. Injection CD95 knockdown SKOV3ip1 cells i.p. into nude mice according to method of well established xenograft ovary cancer animal model again shows a reduced tumor load and this is also confirmed by using a early passage human ovary cancer cell line MONTY-1. Human neutralizing anti-CD95L mAb (NOK-1) rather than mouse anti-CD95 mAb (MFL3) injection into these xenografted nude mice significantly reduced the tumor load, indicating that it's the CD95L secreted by tumor cells rather than the mice microenviroment that stimulates the tumor proliferation. Knocking down FasL expression from the six tumor cell lines mentioned above reduced cell proliferation even more dramatically than knocking down Fas and some cell lines, like HepG2, CAKI-1, MCF7 and HeyA8, even stop growing with reduced FasL expression. The reduced tumor formation by losing FAS/CD95 was also confirmed in vivo in two animal models: DEN induced liver cancer model by using FAS/CD95 liver specific knockout mice and Ade-Cre induced ovary cancer mouse model by generating Fas knockout mice from a mice stain with background of mutated k-ras and deleted Pten expression (LSK-K-ras(G12D/+)Pten(loxP/loxP)). The tumorigenic activity of CD95 is further identified as mediated through the CD95L-CD95-JNK-c-Jun-Fos and EGR1 pathway. These results demonstrate that CD95 plays a major growth promoting role during tumorigenesis and suggest that efforts to inhibit its activity rather than to enhance its activation should be considered during cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-341.

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

Considering Fas ligand as a target for therapy.

The Fas Ligand As a Cell Death Factor and Signal Transducer

TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance.

Slowly getting a clue on CD95 ligand biology.

Activation‐dependent FasL Expression in T Lymphocytes and Natural Killer Cells

Activated Cytotoxic Lymphocytes Promote Tumor Progression by Increasing the Ability of 3LL Tumor Cells to Mediate MDSC Chemoattraction Via Fas Signaling.

Apoptosis and Potential Immunoregulation Mediated by Fas Molecular

Activated T cell exosomes promote tumor invasion via Fas signaling pathway.

Fas Ligand Expression in Colon Cancer: A Possible Mechanism of Tumor Immune Privilege

Loss of Fas Expression and High Expression of HLA-E Promoting the Immune Escape of Early Colorectal Cancer Cells.

Abstract LB-341: CD95/FAS promotes tumorigenesis

Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression

FasL Expression in Human Colon Carcinomas

The Multifaceted Role of Fas Signaling in Immune Cell Homeostasis and Autoimmunity

Regulation of the Proinflammatory Effects of Fas Ligand (CD95L)

Suppression of Tumor Cell Immune Counterattack by Blocking FasL Expression in Pancreatic Cancer Cells

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status